Page 4 - Carmen Bozic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease

Vertex Pharmaceuticals Incorporated today announced that inaxaplin (VX-147) has advanced into the Phase 3 portion of the global Phase 2/3 pivotal clinical trial in APOL1-mediated kidney disease (AMKD), where a 45 mg once daily oral dose will be.

City ofUnited kingdomUnited statesCarmen bozicGlenn chertowGlennm chertowVertex pharmaceuticals incorporated nasdaqExchange commissionProduct serviceProgram steering committeeStanford university school of medicineData monitoring committeeDrug administrationGlobal medicines developmentEuropean medicines agencyCompanies to work

Next-in-class combination therapy shows potential in cystic fibrosis

Next-in-class combination therapy shows potential in cystic fibrosis
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.

Bonnie ramseyCarmen bozicDrug administrationEuropean medicines agencyUniversity of washington school medicineCf foundation therapeutics development networkGlobal medicines developmentVertex pharmaceuticalsModulator steering committeeProfessor emeritaWashington schoolSenior consultantTherapeutics development networkExecutive vice presidentMedical affairsChief medical officer

Vertex shares positive late-stage results for triple combination cystic fibrosis treatment

Vertex shares positive late-stage results for triple combination cystic fibrosis treatment
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

Carmen bozicTrikafta kaftrioVertex pharmaceuticals

In Phase 3 CF trials, vanza triple CFTR modulator therapy bests Trikafta

In Phase 3 CF trials, vanza triple CFTR modulator therapy bests Trikafta
cysticfibrosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cysticfibrosisnewstoday.com Daily Mail and Mail on Sunday newspapers.

Bonnie ramseyCarmen bozicVertex pharmaceuticalsUniversity of washington school medicineWashington school

Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-

– Treatment with the once-daily vanza triple CFTR modulator regimen met all primary and key secondary endpoints in two randomized controlled trials in people with CF ages 12 years and older –– Results were more pronounced in the single-arm study in children ages 6 to 11 years, demonstrating the potential that treati.

Heather nicholsBonnie ramseyCarmen bozicCf foundation therapeutics development networkUniversity of washington school medicineGlobal medicines developmentVertex pharmaceuticals incorporatedVertex pharmaceuticals incorporated nasdaqDrug administrationTreatment groupEuropean medicines agencyModulator steering committeeExecutive vice presidentMedical affairsChief medical officerProfessor emerita